Guggenheim Capital LLC Protagonist Therapeutics, Inc Transaction History
Guggenheim Capital LLC
- $14 Billion
- Q3 2024
A detailed history of Guggenheim Capital LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Guggenheim Capital LLC holds 7,898 shares of PTGX stock, worth $320,658. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7,898Holding current value
$320,658% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PTGX
# of Institutions
248Shares Held
56.7MCall Options Held
76.3KPut Options Held
114K-
Farallon Capital Management LLC San Francisco, CA5.86MShares$238 Million1.32% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$234 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$220 Million3.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$171 Million0.0% of portfolio
-
State Street Corp Boston, MA3.18MShares$129 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $1.99B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...